Identification of profiles associated with conversions between the Alzheimer's disease stages, using a machine learning approach.
Alzheimer’s disease
Conversion
Decision tree
Dementia
Machine learning
Mild cognitive impairment
Journal
Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643
Informations de publication
Date de publication:
26 Jul 2024
26 Jul 2024
Historique:
received:
04
08
2023
accepted:
16
07
2024
medline:
27
7
2024
pubmed:
27
7
2024
entrez:
26
7
2024
Statut:
epublish
Résumé
The identification of factors involved in the conversion across the different Alzheimer's disease (AD) stages is crucial to prevent or slow the disease progression. We aimed to assess the factors and their combination associated with the conversion across the AD stages, from mild cognitive impairment to dementia, at a mild, moderate or severe stage and to identify profiles associated with earliest/latest conversion across the AD stages. In this study conducted on the real-life MEMORA cohort data collected from January 1, 2013, and December 31, 2019, three cohorts were selected depending on the baseline neurocognitive stage from a consecutive sample of patients attending a memory center, aged between 50 and 90 years old, with a diagnosis of AD during the follow-up, and with at least 2 visits at 6 months to 1 year of interval. A machine learning approach was used to assess the relationship between factors including socio-demographic characteristics, comorbidities and history of diseases, prescription of drugs, and geriatric hospitalizations, and the censored time to conversion from mild cognitive impairment to AD dementia, from the mild stage of dementia to the moderate or severe stages of AD dementia, and from the moderate stage of AD dementia to the severe stage. Profiles of earliest/latest conversion compared to median time to conversion across stages were identified. The median time to conversion was estimated with a Kaplan-Meier estimator. Overall, 2891 patients were included (mean age 77±9 years old, 65% women). The median time of follow-up was 28 months for mild cognitive impairment (MCI) patients, 33 months for mild AD dementia and 30 months for moderate AD dementia. Among the 1264 patients at MCI stage, 61% converted to AD dementia (median time to conversion: 25 months). Among the 1142 patients with mild AD dementia, 59% converted to moderate/severe stage (median time: 23 months) and among the 1332 patients with moderate AD dementia, 23% converted to severe stage (Q3 time to conversion: 22 months). Among the studied factors, cardiovascular comorbidities, anxiety, social isolation, osteoporosis, and hearing disorders were identified as being associated with earlier conversion across stages. Symptomatic treatment i.e. cholinesterase inhibitors for AD was associated with later conversion from mild stage of dementia to moderate/severe stages. This study based on a machine learning approach allowed to identify potentially modifiable factors associated with conversion across AD stages for which timely interventions may be implemented to delay disease progression.
Sections du résumé
BACKGROUND
BACKGROUND
The identification of factors involved in the conversion across the different Alzheimer's disease (AD) stages is crucial to prevent or slow the disease progression. We aimed to assess the factors and their combination associated with the conversion across the AD stages, from mild cognitive impairment to dementia, at a mild, moderate or severe stage and to identify profiles associated with earliest/latest conversion across the AD stages.
METHODS
METHODS
In this study conducted on the real-life MEMORA cohort data collected from January 1, 2013, and December 31, 2019, three cohorts were selected depending on the baseline neurocognitive stage from a consecutive sample of patients attending a memory center, aged between 50 and 90 years old, with a diagnosis of AD during the follow-up, and with at least 2 visits at 6 months to 1 year of interval. A machine learning approach was used to assess the relationship between factors including socio-demographic characteristics, comorbidities and history of diseases, prescription of drugs, and geriatric hospitalizations, and the censored time to conversion from mild cognitive impairment to AD dementia, from the mild stage of dementia to the moderate or severe stages of AD dementia, and from the moderate stage of AD dementia to the severe stage. Profiles of earliest/latest conversion compared to median time to conversion across stages were identified. The median time to conversion was estimated with a Kaplan-Meier estimator.
RESULTS
RESULTS
Overall, 2891 patients were included (mean age 77±9 years old, 65% women). The median time of follow-up was 28 months for mild cognitive impairment (MCI) patients, 33 months for mild AD dementia and 30 months for moderate AD dementia. Among the 1264 patients at MCI stage, 61% converted to AD dementia (median time to conversion: 25 months). Among the 1142 patients with mild AD dementia, 59% converted to moderate/severe stage (median time: 23 months) and among the 1332 patients with moderate AD dementia, 23% converted to severe stage (Q3 time to conversion: 22 months). Among the studied factors, cardiovascular comorbidities, anxiety, social isolation, osteoporosis, and hearing disorders were identified as being associated with earlier conversion across stages. Symptomatic treatment i.e. cholinesterase inhibitors for AD was associated with later conversion from mild stage of dementia to moderate/severe stages.
CONCLUSION
CONCLUSIONS
This study based on a machine learning approach allowed to identify potentially modifiable factors associated with conversion across AD stages for which timely interventions may be implemented to delay disease progression.
Identifiants
pubmed: 39061107
doi: 10.1186/s13195-024-01533-5
pii: 10.1186/s13195-024-01533-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
166Informations de copyright
© 2024. The Author(s).
Références
Dufournet M, Dauphinot V, Moutet C, Verdurand M, Delphin-Combe F, Krolak-Salmon P. Impact of cognitive, functional, behavioral disorders, and caregiver burden on the risk of nursing home placement. J Am Med Dir Assoc. 2019;S1525–8610(19):30322–6.
Cepoiu-Martin M, Tam-Tham H, Patten S, Maxwell CJ, Hogan DB. Predictors of long-term care placement in persons with dementia: a systematic review and meta-analysis: predictors of LTC placement in persons with dementia. International Journal of Geriatric Psychiatry. 2016;31:1151-71.
Alzheimer’s Association. Alzheimer’s disease facts and figures. Alzheimers Dement. 2022;18(4):700–89.
Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63–75.
pubmed: 23305823
doi: 10.1016/j.jalz.2012.11.007
Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet Commisions. 2020;396(10248):413–46.
doi: 10.1016/S0140-6736(20)30367-6
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. The Lancet. 2011;377:1019-31.
van Abellan G, Rolland Y, Nourhashémi F, Coley N, Andrieu S, Vellas B. Cardiovascular disease risk factors and progression of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2009;27(3):240–6.
doi: 10.1159/000203365
Musicco M, Palmer K, Salamone G, Lupo F, Perri R, Mosti S, et al. Predictors of progression of cognitive decline in Alzheimer’s disease: the role of vascular and sociodemographic factors. J Neurol. 2009;256:1288–95.
pubmed: 19353221
pmcid: 2721961
doi: 10.1007/s00415-009-5116-4
Cooper C, Sommerlad A, Lyketsos CG, Livingston G. Modifiable predictors of dementia in mild cognitive impairment: a systematic review and meta-analysis. Am J Psychiatry. 2015;172(4):323–34.
pubmed: 25698435
doi: 10.1176/appi.ajp.2014.14070878
McGrattan AM, Pakpahan E, Siervo M, Mohan D, Reidpath DD, Prina M, et al. Risk of conversion from mild cognitive impairment to dementia in low- and middle‐income countries: a systematic review and meta-analysis. Alzheimers Dement. 2022;8(1):e12267.
Wu X, Peng C, Nelson PT, Cheng Q. Deep learning algorithm reveals probabilities of stage-specific time to conversion in individuals with neurodegenerative disease LATE. Alzheimer Dement. 2022;8:e12363.
doi: 10.1002/trc2.12363
Sharma R, Anand H, Badr Y, Qiu RG. Time-to-event prediction using survival analysis methods for Alzheimer’s disease progression. Alzheimers Dement. 2021;7(1):e12229.
Wu X, Peng C, Nelson P, Cheng T. Machine learning approach predicts probability of time to stage-specific conversion of Alzheimer’s disease. J Alzheimer Dis. 2022;90(2):891–903.
doi: 10.3233/JAD-220590
Franciotti R, Nardini D, Russo M, Onofrj M, Sensi SL. Comparison of machine learning-based approaches to predict the conversion to Alzheimer’s disease from mild cognitive impairment. Neuroscience. 2023:S03306-4522(23).
Dauphinot V, Moutet C, Rouch I, Verdurand M, Mouchoux C, Delphin-Combe F, et al. A multicenter cohort study to investigate the factors associated with functional autonomy change in patients with cognitive complaint or neurocognitive disorders: the MEMORA study protocol. BMC Geriatr. 2019;19(1):191.
pubmed: 31319809
pmcid: 6637582
doi: 10.1186/s12877-019-1204-1
Dauphinot V, Garnier-crussard A, Moutet C, Delphin-Combe F, Späth HM, Krolak-Salmon P. Determinants of medical direct costs of care among patients of a memory center. J Prev Alzheimers Dis. 2021;8(3):351–61.
pubmed: 34101794
Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–94.
pubmed: 15324362
doi: 10.1111/j.1365-2796.2004.01388.x
Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnosis guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–9.
pubmed: 21514249
doi: 10.1016/j.jalz.2011.03.008
McKhann G, Knopman D, Chertkow H, Hyman B, Jack Cj, Kawas C, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association worgroups on diagnosis guidelines for Alzheimer’s disease. Alzheimer Dement. 2011;7(3):263–9.
doi: 10.1016/j.jalz.2011.03.005
Folstein M, Folstein S. Mini-mental state: a practical method for grading the cognitive stade of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.
pubmed: 1202204
doi: 10.1016/0022-3956(75)90026-6
Perneczky R, Wagenpfeil S, Komossa K, Grtimmer T, Diehl J, Kurz A. Mapping scores onto stages: mini-mental state examination and clinical dementia rating. Am J Geriatr Psychiatry. 2006;14(2):139–44.
pubmed: 16473978
doi: 10.1097/01.JGP.0000192478.82189.a8
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–81.
doi: 10.1080/01621459.1958.10501452
Leblanc M, Crowley J. Survival trees by goodness of split. J Am Stat Assoc. 1993;88(422):457–67.
doi: 10.1080/01621459.1993.10476296
Huisman T, van der Linder J, Demirovic E. Optimal survival trees: a dynamic programming approach. In Proceedings of AAAI-24. 2024.
Esnault C, Gadonna ML, Queyrel M, Templier A, Zucker JD. Q-Finder: an algorithm for credible subgroup discovery in clinical data analysis — an application to the international diabetes management practice study. Front Artif Intell. 2020;17(3):559927.
doi: 10.3389/frai.2020.559927
Iadecola C, Duering M, Hachinski V, Joutel A, Pendlebury ST, Schneider JA, et al. Vascular cognitive impairment and dementia. J Am Coll Cardiol. 2019;73(25):3326–44.
pubmed: 31248555
pmcid: 6719789
doi: 10.1016/j.jacc.2019.04.034
Ravaglia G, Forti P, Maioli F, Martelli M, Servadei L, Brunetti N, et al. Conversion of mild cognitive impairment to dementia: predictive role of mild cognitive impairment subtypes and vascular risk factors. Dement Geriatr Cogn Disord. 2006;21(1):51–8.
pubmed: 16276110
doi: 10.1159/000089515
Faraco G, Iadecola C. Hypertension: a harbinger of stroke and dementia. Hypertension. 2013;62(5):810–7.
pubmed: 23980072
doi: 10.1161/HYPERTENSIONAHA.113.01063
Heywood R, Gao Q, Nyunt MSZ, Feng L, Chong MS, Lim WS, et al. Hearing loss and risk of mild cognitive impairment and dementia: findings from the Singapore longitudinal ageing study. Dement Geriatr Cogn Disord. 2017;43(5–6):259–68.
pubmed: 28420004
doi: 10.1159/000464281
Zhou B, Lin C-L, Kojima S, Fukushima M, Hsu CY. Risk factors of dementia in patients with cerebral vascular diseases based on Taiwan National Health Insurance data. Dement Geriatr Cogn Disord. 2023.
Kostev K, Hadji P, Jacob L. Impact of osteoporosis on the risk of dementia in almost 60,000 patients followed in general practices in Germany. J Alzheimer Dis. 2018;65(2):401–7.
doi: 10.3233/JAD-180569
Shaw BA, Yang T-C, Kim S. Living alone during old age and the risk of dementia: assessing the cumulative risk of living alone. J Gerontol B Psychol Sci Soc Sci. 2023;78(2):293–301.
pubmed: 36179214
doi: 10.1093/geronb/gbac156
Grande G, Liborio Vetrano D, Cova I, Pomati S, Mattavelli D, Maggiore L, et al. Living alone and dementia incidence: a clinical-based study in people with mild cognitive impairment. J Geriatr Psychiatry Neurol. 2018;31(3):107–13.
pubmed: 29739278
doi: 10.1177/0891988718774425
Desai R, John A, Stott J, Charlesworth G. Living alone and risk of dementia: a systematic review and meta-analysis. Ageing Res Rev. 2020;62:101122.
pubmed: 32659336
doi: 10.1016/j.arr.2020.101122
Beam CR, Kaneshiro C, Jang JY, Reynolds CA, P NL, Gatz M. Differences between women and men in incidence rates of Dementia and Alzheimer’s disease. J Alzheimer’s disease: JAD. 2018;64(4):1077–83.
pubmed: 30010124
doi: 10.3233/JAD-180141
Karp A, Kareholt I, Qiu C, Bellander T, Winblad B, Fratiglioni L. Relation of education and occupation-based socioeconomic status to incident Alzheimer’s disease. Am J Epidemiol. 2004;159(2):175–83.
pubmed: 14718220
doi: 10.1093/aje/kwh018
Tifratene K, Sakarovitch C, Rouis A, Pradier C, Robert P. Mild cognitive impairment and anti-alzheimer disease medications: a cross sectional study of the French National Alzheimer Databank (BNA). J Alzheimer Dis. 2014;38(3):541–9.
doi: 10.3233/JAD-131103
Kelley BJ. Treatment of mild cognitive impairment. Curr Treat Options Neurol. 2015;17(9):372.
pubmed: 26208489
doi: 10.1007/s11940-015-0372-3
Weinstein AM, Barton C, Ross L, Kramer JH, Yaffe K. Treatment practices of mild cognitive impairment in California Alzheimer’s disease centers. J Am Geriatr Soc. 2009;57(4):686–90.
pubmed: 19392962
pmcid: 2773021
doi: 10.1111/j.1532-5415.2009.02200.x
Fink HA, Jutkowitz E, Riley McCarten J, Hemmy LS, Butler M, Davila H, et al. Pharmacologic interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer-type dementia: a systematic review. Ann Intern Med. 2018;168(1):39–51.
pubmed: 29255847
doi: 10.7326/M17-1529
O’Brien J, Burns A. Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British association for. Psychopharmacol J Psychopharmacol. 2011;25(8):997–1019.
pubmed: 21088041
doi: 10.1177/0269881110387547
Russ T, Morling J. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev. 2012;2012(9):CD009132.
pubmed: 22972133
pmcid: 6464825
Rountree S, Atri A, Lopez O, Doody R. Effectiveness of antidementia drugs in delaying Alzheimer’s disease progression. Alzheimers Dement. 2013;9(3):338–45.
pubmed: 23102979
doi: 10.1016/j.jalz.2012.01.002
Areosa SA, Sheriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005;20(3):CD003154.
Stafford J, Chung WT, Sommerlad A, Kirkbride JB, Howard R. Psychiatric disorders and risk of subsequent dementia: systematic review and meta-analysis of longitudinal studies. Int J Geriatr Psychiatry. 2022;37(5):101002.
doi: 10.1002/gps.5711
Scarmeas N, Albert SM, Manly JJ, Stern Y. Education and rates of cognitive decline in incident Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2006;77(3):308–16.
pubmed: 16484637
pmcid: 2077720
doi: 10.1136/jnnp.2005.072306
Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet Neurol. 2012;11(11):1006–12.
pubmed: 23079557
pmcid: 3507991
doi: 10.1016/S1474-4422(12)70191-6
Albrecht P, Perisse J, Sauleau E, Blanc F. Cognitive reserve, one of the determinants of the progression of Alzheimer’s disease. Geriatr Psychol Neuropsychiatr Vieil. 2021;19(2):229–35.
pubmed: 34080985
Le Duff F, Develay AE, Quetel J, Lafay P, Schuck S, Pradier C, et al. The 2008–2012 French Alzheimer plan: description of the National Alzheimer information system. J Alzheimer Dis. 2012;29(4):891–902.
doi: 10.3233/JAD-2012-111943
Goldstein BA, Navar AM, Pencina MJ, Ioannidis JPA. Opportunities and challenges in developing risk prediction models with electronic health records data: a systematic review. J Am Med Inf Assoc. 2017;24(1):198–208.
doi: 10.1093/jamia/ocw042
Jack CR Jr., Bennett DA, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S, et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimer Dement. 2018;14(4):535–62.
doi: 10.1016/j.jalz.2018.02.018